• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Biomol Struct Dyn. Novel oseltamivir-resistant mutations distant from the active site of influenza B neuraminidase

tetano

Editor, Senior Moderator
J Biomol Struct Dyn. 2020 May 14:1-17. doi: 10.1080/07391102.2020.1765872. [Epub ahead of print]
Novel oseltamivir-resistant mutations distant from the active site of influenza B neuraminidase.


Kato Y[SUP]1,[/SUP][SUP]2[/SUP], Takahashi K[SUP]3[/SUP], Ito F[SUP]2[/SUP], Suzuki S[SUP]2[/SUP], Fukui K[SUP]1[/SUP], Mimaki M[SUP]3[/SUP], Suzuki K[SUP]2[/SUP].

Author information




Abstract

We performed a neuraminidase sequence analysis of thirty-two pediatric patients with influenza B who visited Teikyo University Hospital from January 2016 to March 2017, and found oseltamivir-resistant samples belonging to the Yamagata and Victoria lineages. Comparison with the neuraminidase sequence of oseltamivir-susceptible B/Brisbane/60/2008 revealed 5 common amino acid substitutions in many of these samples. According to the binding free energy calculation, the N340D and E358K substitutions reduced the affinity of oseltamivir to neuraminidase. Unexpectedly, these substitutions were located distant from the oseltamivir-binding site in neuraminidase. According to the molecular dynamics simulations, the N340D substitution rearranged complicated hydrogen bond networks in an extensive surface region of neuraminidase. The E358K substitution extensively altered the electrostatic potential map of the overall neuraminidase structure. Through these novel mechanisms, the N340D and E358K substitutions indirectly influenced the affinity reduction. These results may be useful for designing drugs for the treatment of oseltamivir-resistant virus infections.



KEYWORDS:

Influenza B; binding free energy; drug resistance; electrostatic potential; hydrogen bond; molecular dynamics; neuraminidase inhibitor; oseltamivir; virus


PMID:32406800DOI:10.1080/07391102.2020.1765872
 
Back
Top Bottom